Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - PubMed
3 hours ago
- #obesity treatment
- #clinical trial
- #GLP-1 receptor agonist
- Bofanglutide, a biweekly GLP-1 receptor agonist, was evaluated for efficacy and safety in Chinese adults with overweight or obesity.
- The study was a randomized, double-blind, placebo-controlled phase 2b trial involving 340 participants.
- Participants were assigned to different dose groups (12 mg Q2W, 18 mg Q2W, 24 mg Q2W, 48 mg Q2W, 24 mg QW) or placebo.
- The primary endpoint was percentage change in body weight from baseline to week 30.
- Bofanglutide showed significant weight reduction (-9.75% to -16.69%) compared to placebo (-1.15%).
- Adverse events were mostly grade 1-2 gastrointestinal events, with higher incidence in the bofanglutide group (83.9%) than placebo (33.3%).
- The trial was conducted in compliance with ethical guidelines and registered on multiple platforms for transparency.